However, its upregulation in other cancers like prostate tumors and its association with poor prognosis suggests it might play a role in melanoma progression by potentially influencing tumor growth, invasion, or immune evasion (Li and Zhu, 2023) in three distinct malignancies that contained SKCM, SARC, and THCA, SLC2A5 acted as a protective factor (Liu et al., 2024). The gene discussed is SLC2A5; the disease is prostate neoplasm.